Dimensional Fund Advisors LP decreased its holdings in Inogen Inc (NASDAQ:INGN) by 0.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 517,022 shares of the medical technology company’s stock after selling 2,501 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.48% of Inogen worth $49,169,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in INGN. Schroder Investment Management Group bought a new position in shares of Inogen during the second quarter valued at approximately $132,000. Ameritas Investment Partners Inc. grew its holdings in shares of Inogen by 6.1% during the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 86 shares during the last quarter. Sei Investments Co. grew its holdings in shares of Inogen by 38.1% during the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Inogen by 17.8% during the second quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after purchasing an additional 307 shares during the last quarter. Finally, Pinebridge Investments L.P. grew its holdings in shares of Inogen by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 33 shares during the last quarter.
Shares of Inogen Inc (NASDAQ:INGN) opened at $115.59 on Friday. The stock has a market capitalization of $2,403.64, a price-to-earnings ratio of 93.98, a PEG ratio of 3.90 and a beta of 1.13. Inogen Inc has a 1-year low of $62.69 and a 1-year high of $130.05.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million during the quarter, compared to analyst estimates of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The company’s revenue for the quarter was up 26.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.25 earnings per share. sell-side analysts forecast that Inogen Inc will post 1.19 earnings per share for the current fiscal year.
INGN has been the subject of several recent research reports. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a report on Tuesday. BidaskClub lowered Inogen from a “buy” rating to a “hold” rating in a report on Tuesday, December 5th. Leerink Swann reissued an “outperform” rating and issued a $120.00 price objective (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, Needham & Company LLC increased their price objective on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $102.71.
In other news, EVP Byron Myers sold 35,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $116.77, for a total value of $4,086,950.00. Following the transaction, the executive vice president now directly owns 48,600 shares of the company’s stock, valued at $5,675,022. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $119.06, for a total transaction of $119,060.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $119,060. The disclosure for this sale can be found here. Insiders sold 81,500 shares of company stock worth $9,267,695 over the last ninety days. 5.31% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/inogen-inc-ingn-shares-sold-by-dimensional-fund-advisors-lp.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.